Heather Feigelson to Trastuzumab
This is a "connection" page, showing publications Heather Feigelson has written about Trastuzumab.
Connection Strength
0.296
-
Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J Natl Cancer Inst. 2024 Aug 01; 116(8):1384-1394.
Score: 0.242
-
Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care. 2012 Nov; 18(11):704-12.
Score: 0.027
-
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
Score: 0.027